What is HC Wainwright’s Estimate for PRAX Q3 Earnings?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Investment analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for shares of Praxis Precision Medicines in a research note issued on Friday, August 7th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($3.86) per share for the quarter, up from their prior estimate of ($3.87). HC Wainwright currently has a “Buy” rating and a $1,201.00 target price on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($14.37) per share. HC Wainwright also issued estimates for Praxis Precision Medicines’ Q4 2026 earnings at ($4.15) EPS, FY2026 earnings at ($14.09) EPS, Q1 2027 earnings at ($2.98) EPS, Q2 2027 earnings at ($2.14) EPS, Q3 2027 earnings at ($0.72) EPS, Q4 2027 earnings at $1.38 EPS, FY2027 earnings at ($4.24) EPS, FY2028 earnings at $36.07 EPS, FY2029 earnings at $91.42 EPS and FY2030 earnings at $139.61 EPS.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its earnings results on Thursday, August 6th. The company reported ($2.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.67) by $0.80.

Other equities analysts also recently issued research reports about the stock. The Goldman Sachs Group started coverage on shares of Praxis Precision Medicines in a research note on Monday, July 13th. They issued a “buy” rating and a $447.00 target price on the stock. Oppenheimer reiterated an “outperform” rating and issued a $650.00 price target (down from $750.00) on shares of Praxis Precision Medicines in a report on Tuesday, June 2nd. Needham & Company LLC raised their price objective on Praxis Precision Medicines from $575.00 to $582.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wedbush reduced their price objective on Praxis Precision Medicines from $166.00 to $162.00 and set an “underperform” rating on the stock in a research note on Tuesday, June 2nd. Finally, Wells Fargo & Company reaffirmed a “positive” rating and issued a $362.00 target price (up from $323.00) on shares of Praxis Precision Medicines in a research report on Friday. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $573.05.

Praxis Precision Medicines Stock Up 1.7%

PRAX opened at $366.96 on Tuesday. Praxis Precision Medicines has a 52-week low of $37.19 and a 52-week high of $382.54. The company has a 50 day moving average of $304.62 and a two-hundred day moving average of $316.08. The company has a market cap of $10.25 billion, a P/E ratio of -28.38 and a beta of 2.78.

Institutional Trading of Praxis Precision Medicines

A number of hedge funds have recently made changes to their positions in PRAX. GAMMA Investing LLC increased its stake in shares of Praxis Precision Medicines by 10.3% in the second quarter. GAMMA Investing LLC now owns 332 shares of the company’s stock worth $111,000 after buying an additional 31 shares during the last quarter. GF Fund Management CO. LTD. boosted its stake in Praxis Precision Medicines by 8.2% during the 4th quarter. GF Fund Management CO. LTD. now owns 490 shares of the company’s stock valued at $144,000 after acquiring an additional 37 shares during the last quarter. KBC Group NV boosted its stake in Praxis Precision Medicines by 5.8% during the 1st quarter. KBC Group NV now owns 715 shares of the company’s stock valued at $230,000 after acquiring an additional 39 shares during the last quarter. Carl P. Sherr & Co. LLC grew its holdings in Praxis Precision Medicines by 8.4% during the 1st quarter. Carl P. Sherr & Co. LLC now owns 972 shares of the company’s stock worth $313,000 after acquiring an additional 75 shares in the last quarter. Finally, CWM LLC grew its holdings in Praxis Precision Medicines by 15.5% during the 4th quarter. CWM LLC now owns 874 shares of the company’s stock worth $258,000 after acquiring an additional 117 shares in the last quarter. Institutional investors and hedge funds own 67.84% of the company’s stock.

Insiders Place Their Bets

In other Praxis Precision Medicines news, Director Jill Desimone sold 11,600 shares of Praxis Precision Medicines stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $311.32, for a total transaction of $3,611,312.00. Following the sale, the director directly owned 2,337 shares in the company, valued at $727,554.84. The trade was a 83.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is currently owned by insiders.

Praxis Precision Medicines News Summary

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $14.09 from a loss of $14.49 and improved its FY2027 forecast to a loss of $4.24 from a loss of $5.33, indicating expectations for a faster path toward profitability.
• Positive Sentiment: The analyst significantly increased projected earnings for FY2028, FY2029 and FY2030 to $36.07, $91.42 and $139.61 per share, respectively. These estimates were raised from $29.24, $82.12 and $125.74, reinforcing the long-term commercial potential of Praxis’ pipeline.
• Positive Sentiment: The $1,201 target implies substantial upside from the stock’s recent trading level, while the continued Buy rating provides additional support for bullish investor sentiment.
• Neutral Sentiment: HC Wainwright projects continued losses through most of 2027, including EPS of negative $2.98 in the first quarter, negative $2.14 in the second quarter and negative $0.72 in the third quarter, before turning profitable with $1.38 EPS in the fourth quarter.
• Negative Sentiment: The firm reduced its Q4 2026 EPS estimate to a loss of $4.15 from a loss of $3.86. Although the Q3 2026 forecast improved slightly to a loss of $3.86 from a loss of $3.87, the revised near-term outlook still reflects significant operating losses.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.